Normalization of array data relies on the assumption that most genes are not altered, which means that the signals for different samples should be scaled to have similar median or average values. However, accumulating evidence suggests that gene expressions could be widely up-regulated in cancers. Our previous results and subsequent finding have shown violation of the assumption led to erroneous 10 interpretations of microarray data. To decipher the global signal features of microarray data from cancer samples, we empirically evaluated a large collection of gene and miRNA expression profiles and copynumber variation arrays. Our results showed that, at the transcriptomic level, genes and miRNAs are widely over-expressed in a large proportion of cancers. In contrast, at the genomic level, global raw signal intensities for methylation and copy number variation show negligible differences between cancer and 15 normal samples. These results force us to re-evaluate the proper use of normalization procedures under different experimental conditions and for different array platforms.
Deciphering global signal features of high-throughput array data from cancers
Normalization of array data relies on the assumption that most genes are not altered, which means that the signals for different samples should be scaled to have similar median or average values. However, accumulating evidence suggests that gene expressions could be widely up-regulated in cancers. Our previous results and subsequent finding have shown violation of the assumption led to erroneous
Introduction
High-throughput array technology is a powerful tool for transcriptome and genome analysis 1, 2, 3, 4, 5 . Gene and miRNA 20 expression microarrays provide quantitative information about the population of RNA species in a cell or tissue 1, 6 . Using microarrays to monitor global transcriptome expression under various conditions has a tremendous influence on modern biological research 1, 6 . Similarly, methylation arrays and SNP 25 technology were developed for the investigation of methylation status and copy number variation on a genome-wide scale, and they have provided insights into cancer mechanisms, biomarker prediction and drug target identification 7, 8, 9, 10 . Typically, array data are subject to multiple sources of variation, 30 including variation in the preparation of the biological sample, scanning effects and the characteristics of the different arrays. Thus, normalization is a critical initial step in data analysis 1, 3, 4, 5 . Usually, the same number or a similar number of DNA/RNA molecules from each sample should be applied to each array so 35 that the total signal intensities will be similar for each sample 3, 11, 12 . Researchers normalize the signal intensities across all arrays to have the same distribution or a similar distribution regardless of the disease state, under the assumption that only a few genes are altered by disease and that similar numbers of 40 genes are up-regulated or down-regulated. Hence, if the cellular sources produce equivalent amounts of DNA/RNA molecules, and if the yields of the molecules and their derivatives are equivalent throughout the experimental manipulation, then the normalized expression data should produce an accurate 45 representation of the relative levels of each gene product ( Figure   1 ) 3, 11, 12 . However, emerging evidence suggested that this commonly used assumption may not hold true in certain situations. Based on a previous analysis of 16 pair-matched cancer and normal gene expression datasets, we observed 50 extensive increases in the microarray signals for the cancer samples 13, 14 . Subsequently, Loven et al. also showed that cells with high levels of c-Myc can amplify their gene expression program, producing two to three times more total RNA and generating cells that are larger than their low-Myc counterparts 15 .
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Recently, we also found that gene expression may be widely upregulated in several non-cancerous complex diseases 16 . In such cases, normalization would distort the global data distribution and lead to erroneous interpretations of gene expression profiles ( Figure 2 ) 13, 15 . 60 c-Myc is just one of the many master transcription factors governing the transcriptional programs in cancers 17, 18, 19 . It is unclear how many cancers show increased transcription and how often it may lead to misinterpretation of genome-wide expression data. More importantly, in addition to mRNA, what are the global
Global over-expression in cancer gene expression data
In previous work, our results showed that genes are extensively up-regulated in cancers. We observed this phenomenon in 14 of the 16 datasets 13 . Recently, we assembled an unbiased collection of 23 pair-matched gene expression datasets for 12 cancer types. 5 For each of the 23 datasets, we computed the median of the raw signal intensities, and we compared the medians between cancer samples and normal samples. The medians of the raw signal intensities in the cancer samples was increased in 21 of the 23 datasets; this was unlikely to happen by chance if the probability 10 of observing a larger median in the cancer-state dataset is 0.5 in each independent dataset (P<0.05, binomial test). The increase in the median signal in the cancer samples was significant (P<0.05, Wilcoxon rank-sum test) in eight datasets and was marginally significant (P<0.1, Wilcoxon rank-sum test) in another four 15 datasets (Supplementary Table 1 ). These results show that the raw signal intensities of cancer samples tend to be significantly or marginally significantly higher in more than half of the datasets (12/23=52%). Because of the low statistical power of detecting significant differences in a 20 small set of samples 21, 22 , we focused next on five larger datasets with at least 35 samples (cancer or normal), and we found that the percentages were increased further 4/5=80% (significantly and marginally significantly). Thus, the assumption that all arrays for a particular cancer would have the same probe intensity 25 distribution regardless of the physiological state might be misleading. Common normalization methods would distort the global over-expression signal distribution and lead to erroneous interpretations of gene expression data (Figure 2 and 3) 13,15 .
Global over-expression in cancer miRNA data 30 Several commonly used normalization methods for miRNA expression are similar to mRNA gene profiling normalization approaches 23, 24 , but the global features in cancers have not been investigated in detail. Using the same criteria as for gene expression datasets, we assembled an unbiased collection of 12 35 pair-matched single-channel miRNA expression datasets for 8 cancer types. The median of the raw signal intensities in the cancer samples was increased in 9 of 12 datasets. The increase in the median signal in the cancer samples was significant (P<0.05, Wilcoxon rank-sum test) in three datasets and marginally 40 significant (P<0.1, Wilcoxon rank-sum test) in one dataset: Table 1) . If we only focus on the five largest miRNA sample datasets with at least 50 samples for each state (cancer or normal), the 45 percentage is 80% (4/5=80%) (significant and marginally significant). Hence, the traditional normalization methods would again distort the global over-expression signal distribution of miRNA expression data (Figure 2 and 3) .
Normalization might over-normalize signals in cancer

50
transcriptome data Based on the results described above, we can see that transcription (for both genes and miRNAs) differs greatly between cancer samples and normal samples. Thus, the underlying assumption for normalization is not satisfied. This 55 means that normalization may over-normalize the global signal features in cancer transcriptome data (Figure 2 and 3) . As illustrated in Figure 2 -C, the raw signal intensities of genes in cancer samples were moderately significantly higher than that in the normal samples, but differentially expressed genes (DEGs) 60 could not be identified after normalization. For example, as illustrated in Figure 3 -B for the mRNA Colon34 dataset, the gene PABPC1L2B was moderately significantly higher (P=6.69x10 -4 , Wilcoxon rank-sum test) in terms of raw signal intensity in the cancer samples, but it was not identified as a DEG by RMA. 65 Thus, this represents a false-negative result. As illustrated in Figure 2 -D, a gene could be selected as a down-regulated differential gene after normalization, even though its raw signal intensities in the cancer samples were similar to those of the normal samples. Figure 3 -C shows another example; the gene 70 PRR12 had similar raw intensities in the cancer samples and the normal samples, but it was identified as significantly downregulated (P=2.06 x10 -2 , Wilcoxon rank-sum test) in the cancer samples by RMA. Thus, it represents a false-positive result. In addition, the expression directions of genes with moderate or low 75 raw signal intensity differences between cancer and normal samples could be reversed after normalization. These results indicate that commonly used normalization methods might overnormalize the data. This can cause many up-regulated differentially expressed genes/miRNAs to be missed, and it can 80 lead to a non-negligible fraction of down-regulated differentially expressed genes/miRNAs in cancer transcriptome data. 85 Next, we focused on the mRNA and miRNA datasets with significant increases in the raw signal intensities in the cancer samples. As shown in Figure 4 , we compared the expression directions of the DEGs detected before and after normalization (RMA, dChip and LVS) in the mRNA colon34 dataset. Our 90 results showed that many genes (1204, 1324, 623) were identified as up-regulated DEGs in the raw signal data, but these genes were not identified as DEGs after RMA, dChip or LVS normalization. Furthermore, 98% (1204/1233), 84% (1324/1575) and 99% (623/627) of the DEGs selected based on the raw signal data were 95 identified as up-regulated DEGs, respectively. Similarly, as shown in Figure 5 , 1017 and 1113 miRNAs were detected as upregulated differentially expressed miRNAs in the raw signal data, but these miRNA were not detected as differentially expressed miRNAs after quantile normalization or LVS in the miRNA 100 Esophagus152 dataset. Furthermore, 100% (1017/1017) and 95% (1113/1166) of the differentially expressed miRNAs selected based on the raw signal data were identified as up-regulated differentially expressed miRNAs. Similar results were observed in the miRNA Colon168 and Esophagus206 datasets 105 ( Supplementary Figures 1 and 2 ). These results indicate that normalization may cause a large fraction of truly up-regulated differentially expressed genes/miRNAs to be overlooked in cancer samples. On the other hand, as shown in Figures 4 and 5 , a large fraction of the genes/miRNAs in mRNA dataset Colon34 110 and miRNA dataset Esophagus152 were identified as downregulated differentially expressed genes/miRNAs after normalization, but these genes/miRNAs were not identified as differentially expressed genes/miRNAs in the raw signal data.
Effect of normalization on the expression directions of differentially expressed genes/miRNAs and the Pearson correlation coefficient distribution
This shows that RMA, quantile normalization, dChip and LVS can produce many false down-regulated differentially expressed genes/miRNAs in cancer samples. Due to the complexity of biological regulation, most functional mechanisms might be explained not by individual differentially 5 expressed genes but by the combined effects of many moderately changed genes 25, 26 . A recent trend is to construct gene coexpression networks based on microarray data 25, 27, 28 . Thus, we have also compared the pair-wise Pearson correlation coefficient distribution before and after normalization for both the mRNA 10 and miRNA arrays. As shown in Figure 6 , in the mRNA Colon34 dataset, 68% of genes pairs tend to be positively correlated before normalization, but this percentage decreases to 50%, 52% or 58% after RMA, dChip or LVS, respectively. Similarly, as shown in Figure 7 , in the miRNA Esophagus152 dataset, 98% of the 15 miRNA pairs tend to be positively correlated before normalization, but this decreases to 54% or 52% after quantile normalization or LVS. Similar results were observed for the miRNA Colon168 and Esophagus206 datasets ( Supplementary  Figures 3 and 4) . Our results show that, before normalization, the 20 genes pairs tend to be positively correlated, but normalization severely affects the signal distribution and causes that tendency to disappear.
Minor differences in raw signal intensities for genomic data between cancer samples and normal samples 25 For methylation and copy number variation array data, although some researchers normalize these data after considering the statistical benefit, most do not perform normalization to avoid systemic bias 3, 9 . Using an unbiased collection of nine pairmatched single-channel datasets based on SNP arrays, we found 30 that, in eight of the nine datasets, the median raw signal intensities in the cancer samples were not significantly different from those of the normal samples. Further analysis has shown that, in six of nine datasets, the raw signal intensities are slightly increased at the 75th quantiles in the cancer samples. Only one 35 dataset (colon188) showed a significant increase of the median and the 75th quantile raw signal intensities (P=1.54x10 -2 and 2.44x10 -2 , respectively) ( Table 2) . Similarly, our previous results also demonstrated that, in all of the eight analyzed methylation datasets, the median raw signal intensities in the cancer samples 40 were not significantly different (P>0.05) from those of normal samples. Further analysis indicated that slightly more genes were hypomethylated in the cancer samples compared to the normal tissues around the 75th quantile 29 . These results suggest that, except for colorectal cancer, normalization algorithms may have 45 more positive effects by reducing technical variations compared to the negative effects that remove biological signals of methylation or copy number variation in array data.
Discussion
Our results show that cancer tissue samples tend to show elevated 50 intensities in most pair-matched cancer and normal expression datasets (21 of 23). Similar results were also observed for miRNA expression datasets (9 of 12). Notably, these samples were taken from a variety of cancer types and were produced by different laboratories around the world. Thus, this phenomenon is 55 not likely to be limited to cancers overexpressing c-Myc. Rather, the up-regulation of mRNA and miRNA products is a general feature of cancer cells. Alterations of many essential cellular functions, which are referred to as cancer hallmarks, collectively dictate malignant growth for almost all human cancers 30,31 , so 60 gene expression could be globally changed in cancer, as evidenced by the fact that we often detect thousands of differentially expressed genes in comparisons of cancer samples with normal controls 13, 32 . On the other hand, the global raw signal distributions of genomic array datasets, such as datasets for 65 methylation or copy number variation, show little difference between cancer and normal samples. This is perhaps because both DNA hypomethylation and hypermethylation have been associated with carcinogenesis in numerous investigations 33, 34 . Similarly, there are both gains and losses of copy number that 70 occur in cancer genomes 35, 36 . Thus, the global raw signals of genomic data may follow similar distributions in both cancer samples and normal samples. These results have great implications for cancer biology. First, we suggest that, at least for cancer microarray data, it is better to 75 compare the raw global signal distributions between cancer and normal samples, as was done in this study. This critical quality control step will enable proper use of normalization methods and more accurate interpretation of array data. Second, when there is the potential for global signal changes in transcriptome data, 80 conventional normalization methods should be used with caution because such analyses are based on an unreliable assumption and may actually distort the biological signals. This may cause more harm than good during the biological analysis of array data. However, in genomics analyses (methylation and copy number 85 variation data), the situation is very different. Our results show that the current practice of avoiding normalization for these types of arrays may represent an over-abundance of caution. In fact, normalization for these arrays can increase the power of detecting differentially methylated sites and SNP changes among many 90 weak and complicated signals. Based on our analysis, we encourage the use of normalization when analyzing genomic array data, but we advise against using normalization uncritically for the analysis of transcriptome data. Finally, we think it is important to comprehensively evaluate the effects of 95 normalization procedures on the subsequent bioinformatics analysis of array data, especially for cancer datasets. For example, if our goal is to find a small number of significant biomarkers for disease diagnosis 37 , normalization might have less of an influence on the results because the most significant 100 differentially expressed genes/miRNAs tend to remain significant after normalization (Figure 2-B, Figure 3 13, 15 , especially for the expression directions of differentially expressed genes/miRNAs and the Pearson correlation coefficient distribution. Finally, we suggest that, at least for transcriptome data from cancer studies, a critical initial step is to evaluate the differences in raw global signal 110 distribution between cancer and normal samples. Additionally, the use of spike-in controls, as suggested by Loven et al. 15 and others 38, 39, 40 , may be a useful, robust, cross-platform quality control method to enable more accurate detection of cancer-associated genes/miRNAs in transcriptome data. Furthmore, we should pay more attention towards optimizing experimental designs and stringently randomizing potential experimental artifacts across biological groups, use of sufficient sample sizes, more conducive to probe hybridization and developing the novel 5 normalization strategy for transcriptome data may also help for the solution of this problem in cancer studies.
Methods
High-throughput omics datasets and signal intensities 10 We specifically selected pair-matched datasets in which the normal samples were taken from the same subjects as the cancer samples, so that the effects of certain variables would be eliminated, such as familial effects, individual effects and environmental differences 13 . Using the NCBI GEO database 20 for 15 gene expression datasets, we obtained an unbiased collection of 23 pair-matched Affymetrix single-channel datasets for 12 cancer types. Each dataset had to include at least 10 samples for each state (cancer and normal). Similarly, we collected a total of 12 pair-matched single-channel miRNA datasets for 8 cancer types. 20 High-density SNP arrays provide a robust, effective method for detecting and analyzing genomic copy number variation 41, 42 , so we also collected 9 pair-matched single-channel datasets for 6 cancer types. All of the datasets that were analyzed in this study are described in Table 3 . 25 For the raw signal intensities of the high-throughput omics data in .cel format, we only used the PM intensities to represent "signal intensity" because it has been shown that ignoring the MM values is preferable for background correction 43, 44 . For .txt and .gpr format data, the background intensities were subtracted from the 30 raw signal intensities to obtain the final signal intensities.
Normalization algorithms and identification of differentially expressed genes
In this work, RMA 44 , quantile 45 and dChip 46 normalization algorithms were used for the mRNA and miRNA data. These that were selected only before or only after normalization. Nonoverlap-down represents the down-regulated miRNAs among differentially expressed miRNAs that were selected only before or only after normalization.
95
Fig. 6 The density distributions of pair-wise Pearson correlation coefficients before and after normalization of the mRNA colon34 dataset. Tables: Table 1 Comparison of the median raw signal intensities of miRNA expression in cancer samples and normal samples. Median of Cancer represents the median of the raw signal intensities in the cancer samples. Median of Normal represents the median of the raw signal intensities in the normal samples. The 75th quantile of cancer is the 75th quantile value of the raw signal intensities in the cancer samples. The 75th quantile of normal is the 75 quantile value of the raw signal intensities in the normal samples. P value: the P value of the medians/75th quantiles between cancer and normal samples according to the Wilcoxon rank-sum test. 
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